Cargando…
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs....
Autores principales: | Griffin, Merope, Scotto, Daniele, Josephs, Debra H., Mele, Silvia, Crescioli, Silvia, Bax, Heather J., Pellizzari, Giulia, Wynne, Matthew D., Nakamura, Mano, Hoffmann, Ricarda M., Ilieva, Kristina M., Cheung, Anthony, Spicer, James F., Papa, Sophie, Lacy, Katie E., Karagiannis, Sophia N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652848/ https://www.ncbi.nlm.nih.gov/pubmed/29100459 http://dx.doi.org/10.18632/oncotarget.19836 |
Ejemplares similares
-
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
por: Ilieva, Kristina M., et al.
Publicado: (2018) -
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
por: Pellizzari, Giulia, et al.
Publicado: (2019) -
In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model
por: Williams, Iwan P., et al.
Publicado: (2019) -
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017) -
Therapeutic targets and new directions for antibodies developed for ovarian cancer
por: Bax, Heather J., et al.
Publicado: (2016)